ForPatients
*by Roche*

Spinal Muscular Atrophy (SMA)

# A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of RO7034067 in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants (SUNFISH)

| Trial Status | Trial Runs In | Trial Identifier |
|---|---|---|
| Completed | 16 Countries | NCT02908685 2016-000750-35 BP39055 |

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

## *Trial Summary:*

Multi-center, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of Risdiplam in adult and pediatric participants with Type 2 and Type 3 SMA. The study consists of two parts, an exploratory dose finding part (Part 1) of Risdiplam for 12 weeks and a confirmatory part (Part 2) of Risdiplam for 24 months.

| Hoffmann-La Roche | Phase 2 |
|---|---|
| Sponsor | Phase |

**NCT02908685 2016-000750-35 BP39055**
Trial Identifiers

## *Eligibility Criteria:*

| Gender | Age | Healthy Volunteers |
|---|---|---|
| All | >= 2 Years & <= 25 Years | No |